Chemistry data
- Class
- GLP-1 receptor agonist (incretin mimetic)
- Molecular weight
- 4113.6 g/mol
- Sequence
- modified 31-amino-acid peptide with Aib8, Arg34, and C18 fatty diacid chain
- Half-life
- approximately 1 week (168 hours)
- Routes
- subcutaneous · oral
- Studied doses
- subcutaneous 0.25 mg to 2.4 mg once weekly (titrated over 16-20 weeks) · subcutaneous 0.5 mg to 2 mg once weekly · oral 3 mg to 14 mg once daily
Status Regulacyjny
- Stany Zjednoczone
- fda_approved
- Unia Europejska
- ema_approved
- Wielka Brytania
- mhra_approved
Jak to działa
- GLP-1 receptor activation and glucose-dependent insulin secretion
- Central appetite suppression via hypothalamic POMC/CART and NPY/AgRP neurons
- Delayed gastric emptying and increased satiety signaling
- AMPK/SIRT1 pathway activation and adipose tissue browning
- NF-κB inhibition and anti-inflammatory macrophage modulation
- SIRT1/NRF2 antioxidant pathway activation
Wyniki badań
- weight-loss phase_3_clinical
- glycemic-control phase_3_clinical
- cardiovascular-risk-reduction phase_3_clinical
- appetite-regulation phase_3_clinical
- metabolic-optimization phase_3_clinical
Kontekst dawkowania
-
- Drogi Podania
- subcutaneous
- Zakres
- 0.25 mg to 2.4 mg once weekly (titrated over 16-20 weeks)
STEP clinical trials for chronic weight management (Wegovy)
-
- Drogi Podania
- subcutaneous
- Zakres
- 0.5 mg to 2 mg once weekly
SUSTAIN trials for type 2 diabetes (Ozempic)
-
- Drogi Podania
- oral
- Zakres
- 3 mg to 14 mg once daily
PIONEER trials for type 2 diabetes (Rybelsus); must be taken on empty stomach with ≤120 mL water ≥30 min before food
🧮 Reconstitution Calculator
Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.
Efekty uboczne: kontekst badań
- nausea (most common, ~44% during titration, typically diminishes)
- vomiting (~24%)
- diarrhea (~30%)
- abdominal pain (~10%)
- constipation (~24%)
- decreased appetite
- injection site reactions
- headache
- fatigue
Pełne podsumowanie badań wkrótce. Tymczasem zajrzyj do danych naukowych i referencji PubMed powyżej.
Powiązane Strony
- semaglutide vs tirzepatide
- semaglutide vs liraglutide
- weight loss
- appetite suppression
- glp 1 agonists
- semaglutide
- semaglutide
- Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity
- Retatrutide
Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease
- Semaglutide vs Retatrutide
Comparison